25  	25  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
small  	small  	 JJ	O
molecular  	molecular  	 JJ	B-NP
weight  	weight  	 NN	I-NP
kinase  	kinase  	 NN	I-NP
inhibitors 	inhibitors 	 NNS	I-NP
:  	:  	 :	O
potentials  	potentials  	 NNS	O
and  	and  	 CC	O
limitations  	limitations  	 JJ	B-NP
Deregulation  	Deregulation  	 NN	I-NP
of  	of  	 IN	I-NP
protein  	protein  	 NN	I-NP
and  	and  	 CC	O
lipid  	lipid  	 JJ	B-NP
kinase  	kinase  	 JJ	I-NP
activities  	activities  	 NNS	I-NP
leads  	leads  	 VBZ	O
to  	to  	 TO	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
pathologies 	pathologies 	 NN	O
,  	,  	 ,	O
ranging  	ranging  	 VBG	O
from  	from  	 IN	O
cancer  	cancer  	 NN	O
inflammatory  	inflammatory  	 JJ	B-NP
diseases 	diseases 	 NNS	I-NP
,  	,  	 ,	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
infectious  	infectious  	 JJ	B-NP
diseases 	diseases 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disorders 	disorders 	 NNS	I-NP
.  	.  	 .	O
Protein  	Protein  	 NN	B-NP
kinases  	kinases  	 NNS	I-NP
and  	and  	 CC	O
lipid  	lipid  	 JJ	B-NP
kinases  	kinases  	 NNS	I-NP
represent 	represent 	 VBP	O
,  	,  	 ,	O
therefore 	therefore 	 RB	O
,  	,  	 ,	O
an  	an  	 DT	O
important  	important  	 JJ	O
target  	target  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
industry 	industry 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
fact 	fact 	 NN	O
,  	,  	 ,	O
approximately  	approximately  	 RB	O
one-third  	one-third  	 JJ	O
of  	of  	 IN	O
all  	all  	 DT	O
protein  	protein  	 NN	B-NP
targets  	targets  	 NNS	I-NP
under  	under  	 IN	O
investigation  	investigation  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
industry  	industry  	 NN	I-NP
are  	are  	 VBP	O
protein  	protein  	 NN	B-NP
or  	or  	 CC	O
lipid  	lipid  	 JJ	B-NP
kinases 	kinases 	 NN	I-NP
.  	.  	 .	O
To  	To  	 TO	O
date 	date 	 NN	O
,  	,  	 ,	O
30  	30  	 CD	O
kinase  	kinase  	 CD	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
approved 	approved 	 VBN	O
,  	,  	 ,	O
which 	which 	 WDT	O
,  	,  	 ,	O
with  	with  	 IN	O
few  	few  	 JJ	O
exceptions 	exceptions 	 NNS	O
,  	,  	 ,	O
are  	are  	 VBP	O
mainly  	mainly  	 RB	O
for  	for  	 IN	O
oncological  	oncological  	 JJ	B-NP
indications  	indications  	 NNS	I-NP
and  	and  	 CC	O
directed  	directed  	 VBN	O
against  	against  	 IN	O
only  	only  	 RB	O
a  	a  	 DT	O
handful  	handful  	 NN	O
of  	of  	 IN	O
protein  	protein  	 NN	B-NP
and  	and  	 CC	O
lipid  	lipid  	 JJ	B-NP
kinases 	kinases 	 NN	I-NP
,  	,  	 ,	O
leaving  	leaving  	 VBG	O
70 	70 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
kinome  	kinome  	 JJ	B-NP
untapped 	untapped 	 NN	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
these  	these  	 DT	O
successes  	successes  	 NNS	O
in  	in  	 IN	O
kinase  	kinase  	 JJ	B-NP
drug  	drug  	 NN	I-NP
discovery 	discovery 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
kinase  	kinase  	 JJ	B-NP
inhibitors  	inhibitors  	 NN	I-NP
with  	with  	 IN	O
outstanding  	outstanding  	 JJ	O
selectivity 	selectivity 	 NN	O
,  	,  	 ,	O
identification  	identification  	 NN	B-NP
and  	and  	 CC	O
validation  	validation  	 NN	B-NP
of  	of  	 IN	I-NP
driver  	driver  	 NN	I-NP
kinase 	kinase 	 NNS	I-NP
( 	( 	 -LRB-	I-NP
s 	s 	 LS	I-NP
)  	)  	 -RRB-	I-NP
in  	in  	 IN	O
diseases 	diseases 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
emerging  	emerging  	 VBG	B-NP
problem  	problem  	 NN	I-NP
of  	of  	 IN	O
resistance  	resistance  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
inhibition  	inhibition  	 NN	O
of  	of  	 IN	O
key  	key  	 JJ	B-NP
target  	target  	 NN	I-NP
kinases  	kinases  	 NNS	I-NP
remain  	remain  	 VBP	O
major  	major  	 JJ	O
challenges 	challenges 	 NNS	O
.  	.  	 .	O
This  	This  	 DT	O
minireview  	minireview  	 NN	B-NP
provides  	provides  	 VBZ	O
an  	an  	 DT	O
insight  	insight  	 NN	O
into  	into  	 IN	O
protein  	protein  	 NN	B-NP
and  	and  	 CC	O
lipid  	lipid  	 JJ	B-NP
kinase  	kinase  	 JJ	I-NP
drug  	drug  	 NN	I-NP
discovery  	discovery  	 NN	I-NP
with  	with  	 IN	O
respect  	respect  	 NN	O
to  	to  	 TO	O
achievements 	achievements 	 NNS	B-NP
,  	,  	 ,	O
binding  	binding  	 JJ	O
modes  	modes  	 NNS	B-NP
of  	of  	 IN	O
inhibitors 	inhibitors 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
novel  	novel  	 NN	O
avenues  	avenues  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
generation  	generation  	 NN	O
of  	of  	 IN	O
second-generation  	second-generation  	 JJ	B-NP
kinase  	kinase  	 JJ	I-NP
inhibitors  	inhibitors  	 NN	I-NP
to  	to  	 TO	O
treat  	treat  	 VB	O
cancers 	cancers 	 NNS	O
.  	.  	 .	O
